Skip to main content

Table 1 Patient demographic characteristics of completer population at baseline (N = 280)

From: The direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results from a randomized placebo-controlled trial

  Lurasidone 20–60 mg/day (N = 90) Lurasidone 80–120 mg/day (N = 96) Placebo (N = 94)
Age, mean (SD) 41.2 (12.9) 41.7 (12.6) 39.1 (11.4)
Male, n (%) 43 (47.8 %) 41 (42.7 %) 44 (46.8 %)
White, n (%) 60 (66.7 %) 62 (64.6 %) 62 (66.0 %)
SDS total score, mean (SD) 10.1 (7.3) 10.0 (7.4) 13.3 (8.3)
MADRS total score, mean (SD) 29.9 (4.7) 29.7 (4.8) 29.8 (4.7)
HAM-A total score, mean (SD) 16.2 (6.6) 14.9 (4.9) 15.6 (6.1)
Q-LES-Q SF total score, mean (SD) 33.4 (13.8) 34.6 (12.8) 36.5 (13.2)
QIDS-SR16 total score, mean (SD) 14.0 (3.7) 14.3 (3.1) 14.5 (3.2)